Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

Under Novo Nordisk’s new proposal, the company would pay $62.20 per Metsera common share in cash, as well as certain employee ...

The first lawsuit, filed on Friday, claims Novo's bid breaches Pfizer's merger agreement and seeks to bypass antitrust review ...

Pfizer sues Metsera and Novo Nordisk for breaching merger agreement and seeks injunction to enforce deal after ...

Metsera stock bidding war intensifies as Novo and Pfizer race to secure next-gen obesity drug assets amid surging market ...

Pfizer has requested a temporary restraining order to keep Metsera from breaking its contract with Pfizer to take a deal with ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker Metsera. Novo is now offering to pay as much as $10 billion for the company, Metsera ...

Metsera said Pfizer and Novo Nordisk both upped their bids to acquire the obesity startup, with Novo’s offer valuing the company for up to $10 billion.

Novo Nordisk and Pfizer have revised their competing bids for Metsera, an obesity drug developer. Novo Nordisk's offer now values the deal at approximately $10 billion, while Pfizer has boosted its ...